Gyre Therapeutics, Inc. Share Price
GYREGyre Therapeutics, Inc. Stock Performance
Open $5.82 | Prev. Close $6.17 | Circuit Range N/A |
Day Range $5.82 - $5.89 | Year Range $5.46 - $9.36 | Volume 1,760 |
Average Traded $5.86 |
Gyre Therapeutics, Inc. Share Price Chart
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-Jul-26 | $5.82 | $5.89 | +0.00% |
20-Jul-26 | $5.82 | $5.89 | -2.56% |
17-Jul-26 | $6.12 | $6.05 | -5.47% |
16-Jul-26 | $6.42 | $6.40 | -2.44% |
15-Jul-26 | $6.45 | $6.56 | +2.74% |
14-Jul-26 | $6.36 | $6.38 | +0.87% |
13-Jul-26 | $6.41 | $6.33 | -2.84% |
FAQs on Gyre Therapeutics, Inc. Share Price
Can I buy Gyre Therapeutics, Inc. shares in India?
What is the share price of Gyre Therapeutics, Inc.?
What is the 5 year returns of Gyre Therapeutics, Inc.?
What are the high & low stock price of Gyre Therapeutics, Inc. today?
What is the 52-week high and low of Gyre Therapeutics, Inc. stock?